Detalhe da pesquisa
1.
PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy.
Cell Immunol
; 397-398: 104805, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38244265
2.
Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities.
Semin Cancer Biol
; 78: 78-89, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626407
3.
The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs.
Breast Cancer Res Treat
; 191(1): 209-217, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34669082
4.
Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease.
J Neurooncol
; 157(2): 249-269, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35244835
5.
Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway.
Mol Ther
; 29(4): 1541-1556, 2021 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33412308
6.
Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
BMC Cancer
; 21(1): 552, 2021 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33992087
7.
Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
BMC Cancer
; 21(1): 223, 2021 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33663447
8.
Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases.
J Neurooncol
; 152(3): 591-601, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33742358
9.
Management of brain metastases in breast cancer: a review of current practices and emerging treatments.
Breast Cancer Res Treat
; 180(2): 279-300, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32030570
10.
Breast leptomeningeal disease: a review of current practices and updates on management.
Breast Cancer Res Treat
; 177(2): 277-294, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31209686
11.
Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy.
Breast Cancer Res Treat
; 175(3): 781-788, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30859348
12.
Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer.
Ann Surg Oncol
; 25(10): 2852-2857, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30014455
13.
Transected thin melanoma: Implications for sentinel lymph node staging.
J Surg Oncol
; 117(4): 567-571, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29194673
14.
The impact of preoperative magnetic resonance imaging and lumpectomy cavity shavings on re-excision rate in pure ductal carcinoma in situ-A single institution's experience.
J Surg Oncol
; 117(4): 558-566, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29127721
15.
Histological immune response patterns in sentinel lymph nodes involved by metastatic melanoma and prognostic significance.
J Cutan Pathol
; 45(6): 377-386, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29446846
16.
Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival.
Breast Cancer Res
; 19(1): 75, 2017 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28666457
17.
Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes.
Ann Surg Oncol
; 24(2): 407-417, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27663569
18.
Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.
Ann Surg Oncol
; 24(10): 2999-3003, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28766212
19.
Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis.
Ann Surg Oncol
; 24(4): 952-959, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27807729
20.
Anti-HER2 CD4+ T-Helper Type 1 Immune Response is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer.
Ann Surg Oncol
; 24(4): 1057-1063, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27826664